[go: up one dir, main page]

WO2011098799A3 - Respiratory disease treatment - Google Patents

Respiratory disease treatment Download PDF

Info

Publication number
WO2011098799A3
WO2011098799A3 PCT/GB2011/050224 GB2011050224W WO2011098799A3 WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3 GB 2011050224 W GB2011050224 W GB 2011050224W WO 2011098799 A3 WO2011098799 A3 WO 2011098799A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
ethoxy
benzyl
hydroxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/050224
Other languages
French (fr)
Other versions
WO2011098799A2 (en
Inventor
Harry Finch
Craig Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Inflammation Ltd
Original Assignee
Pulmagen Therapeutics Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics Inflammation Ltd filed Critical Pulmagen Therapeutics Inflammation Ltd
Publication of WO2011098799A2 publication Critical patent/WO2011098799A2/en
Anticipated expiration legal-status Critical
Publication of WO2011098799A3 publication Critical patent/WO2011098799A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition containing the compound 5-{4-[2-(5-ethyl-pyridin-2-yl)-2-hydroxy-ethoxy]-benzyl}-thiazolidine-2,4-dιone, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and/or excipients, characterised in that at least 95% by weight of the 5-{4-[2-(5-ethyl-pyridin-2-yl)-2- hydroxy-ethoxy]-benzyl}-thiazolidine-2,4-dione content of the composition is the diastereomeric form 5(R)-{4-[2-(5-ethyl-pyridin-2-yI)=2(S)-hydroxy-ethoxy]=benzyl}- thiazolidιne-2,4-dione and less than 5% by weight is one or more of the other three diastereomeric forms.
PCT/GB2011/050224 2010-02-10 2011-02-09 Respiratory disease treatment Ceased WO2011098799A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1002224.2A GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment
GB1002224.2 2010-02-10

Publications (2)

Publication Number Publication Date
WO2011098799A2 WO2011098799A2 (en) 2011-08-18
WO2011098799A3 true WO2011098799A3 (en) 2015-09-11

Family

ID=42110492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/050224 Ceased WO2011098799A2 (en) 2010-02-10 2011-02-09 Respiratory disease treatment

Country Status (2)

Country Link
GB (1) GB201002224D0 (en)
WO (1) WO2011098799A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JP6800013B2 (en) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ Deuterated 2,4-thiazolidinedione and treatment methods
ES2831326T3 (en) 2014-01-15 2021-06-08 Poxel Sa Methods to treat neurological, metabolic, and other disorders using deuterium-enriched enantiopure pioglitazone
KR20170045750A (en) * 2014-09-08 2017-04-27 고담 바이오파마슈티컬스 인크. Methods of Treating Pulmonary Sarcoidosis
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
WO2010015818A1 (en) * 2008-08-07 2010-02-11 Argenta Discovery Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6235216A (en) 1985-08-09 1987-02-16 Noritoshi Nakabachi Method and device for measuring thickness of heterogeneous material layer nondestructively
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
WO2000021143A1 (en) 1998-10-05 2000-04-13 Osram Opto Semiconductors Gmbh & Co. Ohg Radiation emitting semiconductor chip
SI20116A (en) 1998-12-02 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Novel procedure of preparation of simvastatine and its analogues
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
WO2001083462A1 (en) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DE10346940B3 (en) 2003-10-06 2005-06-16 Schering Ag Substituted pentanols, their use for the preparation of medicaments, in particular anti-inflammatories and pharmaceutical compositions containing them
KR100889426B1 (en) 2000-08-05 2009-03-23 글락소 그룹 리미티드 6.alpha., 9.alpha.-difluoro-17.alpha .- '(2-furanylcarboxyl) oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo as anti-inflammatory -Androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester
WO2002013812A1 (en) 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (en) 2001-03-08 2007-07-15 Glaxo Group Ltd AGONISTS OF BETA-ADRENORECEPTORS
DE60224172T2 (en) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford FORMANILID DERIVATIVES AS BETA2 ADRENOR RECEPTOR AGONISTS
EP1395604B1 (en) 2001-06-12 2008-06-25 Glaxo Group Limited Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
CN101701006B (en) 2001-09-14 2014-03-05 葛兰素集团有限公司 Phenylethanolamine derivatives for the treatment of respiratory diseases
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (en) 2002-08-09 2005-04-27 Novartis Ag COMPOUNDS DERIVED FROM TIAZOL 1,3-2-ONA, PHARMACEUTICAL COMPOSITION AND COMPOSITE PREPARATION PROCESS
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (en) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia
JP4490911B2 (en) 2002-10-11 2010-06-30 ファイザー・インク Indole derivatives as β-2 agonists
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
DE60315492T2 (en) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford MEDICALLY USEFUL ARYLETHANOLAMINE COMPOUNDS
DK1556342T3 (en) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253220A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD
DE10253282A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
DE10258695A1 (en) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(2-hydroxy-2-(3-methylsulfonylamino-4-hydroxyphenyl)ethylamino-4-(pyrid-2-ylamino)-2-methylbutane used e.g. for treating asthma and chronic obstructive pulmonary disease
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
PL1613315T3 (en) 2003-04-04 2009-07-31 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
ES2298757T3 (en) 2003-06-04 2008-05-16 Pfizer Inc. DERIVATIVES OF Z-AMINO-PIRIDINA AS BETA-2 ADRECORRECEPTORS AGONISTS.
EA200600148A1 (en) 2003-07-01 2006-08-25 Шеринг Акциенгезельшафт HETEROCYCLICALLY SUBSTITUTED DERIVATIVES OF PENTANOL, METHOD OF THEIR RECOVERY AND THEIR APPLICATION AS INFLAMMATION INHIBITORS
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
DE10347385A1 (en) 2003-10-08 2005-05-12 Schering Ag Rearranged pentanols, a process for their preparation and their use as anti-inflammatory agents
BRPI0415209A (en) 2003-10-08 2006-12-05 Schering Ag tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US8241489B2 (en) 2003-12-19 2012-08-14 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (en) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
RS50561B (en) 2004-01-22 2010-05-07 Pfizer Inc. SULFONAMIDE DERIVATIVES FOR TREATMENT OF DISEASES
JP4036343B2 (en) 2004-01-22 2008-01-23 ファイザー・インク Sulfonamide derivatives for the treatment of diseases
DE102004003428A1 (en) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting beta-2 agonists, and their use as pharmaceuticals
EP1720546B1 (en) 2004-02-14 2010-09-01 Boehringer Ingelheim International GmbH Novel, sustained-action beta-2-agonists and their use as medicaments
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
EP1577306A1 (en) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases
HN2004000023A (en) 2004-03-22 2007-11-23 Mars Inc ANIMAL MASCADURE
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
PL1730103T3 (en) 2004-03-23 2010-10-29 Pfizer Formamide derivatives useful as adrenoceptor
WO2005092860A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
EP1730141B1 (en) 2004-03-23 2009-05-27 Pfizer Limited Compounds for the treatment of diseases
EP1595873A1 (en) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituted cycloalkyl derivatives for the treatment of respiratory diseases
JP2007537187A (en) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hydroxy-substituted benzofused heterocyclic compounds for use as beta agonists in the treatment of respiratory diseases
DE102004024451A1 (en) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
DE102004024454A1 (en) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
WO2005121065A2 (en) 2004-06-03 2005-12-22 Theravance, Inc. DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
WO2006016245A1 (en) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2008512470A (en) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド Amidine-substituted arylaniline compounds
DE102004045648A1 (en) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New betamimetics for the treatment of respiratory diseases
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200745099A (en) 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives
ES2654908T3 (en) 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Thiazolidinedione analogues for the treatment of diseases mediated by metabolic inflammation
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109088A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
WO2010015818A1 (en) * 2008-08-07 2010-02-11 Argenta Discovery Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAMALI B ET AL: "Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 46, no. 1, 7 January 2008 (2008-01-07), pages 82 - 87, XP002587887, ISSN: 0731-7085, [retrieved on 20070910], DOI: DOI:10.1016/J.JPBA.2007.09.004 *
NARALA VENKATA R ET AL: "Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 8, no. 1, 4 December 2007 (2007-12-04), pages 90, XP021031353, ISSN: 1465-9921 *
PARKS D J ET AL: "Differential activity of rosiglitazone enantiomers at PPARgamma", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 8, no. 24, 15 December 1998 (1998-12-15), pages 3657 - 3658, XP004819411, ISSN: 0960-894X, DOI: DOI:10.1016/S0960-894X(98)00664-7 *
TANIS S P ET AL: "Synthesis and biological activity of metabolites of the antidiabetic antihyperglycemic agent Pioglitazone", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 26, 1 January 1996 (1996-01-01), pages 5053 - 5063, XP002336054, ISSN: 0022-2623, DOI: DOI:10.1021/JM9605694 *

Also Published As

Publication number Publication date
GB201002224D0 (en) 2010-03-31
WO2011098799A2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
GB2465897A (en) Respiratory disease treatment
WO2011098799A3 (en) Respiratory disease treatment
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2010068810A3 (en) Certain substituted amides, method of making, and method of use thereof
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
EA201490014A1 (en) MODIFIED 4-METHYL-3 - [[4- (3-PYRIDINIL) -2-PYRIMIDINYL] AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFTOROMETHYL) FENYL ISOLATED ] BENZAMIDE, SILUBILIZED WITH THE USE OF ORGANIC ACIDS
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
NZ596154A (en) Cyclic compound having substituted phenyl group
WO2012032360A3 (en) Novel use
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
IL205974A (en) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof for use as a medicament and pharmaceutical composition comprising said compound
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2008137779A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EP2141155A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST HYPERLIPEMIA
NO20084853L (en) Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
EP3276004A3 (en) Methods for treating chronic kidney disease
MX2014002471A (en) Synergistic combinations of pi3k- and mek-inhibitors.
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n-methylbenzofuran-3-carboxamide compounds, pharmaceutically acceptable salts thereof and pharmaceutical composition comprising them
EP1774968A4 (en) BENZYLISOQUINOLEIN DERIVATIVE OR BISBENZYLISOQUINOLEIN DERIVATIVE - CONTAINING PSYCHOTROPIC, ANALGESIC AND / OR ANTIPHLOGISTIC AGENT, AND HEALTH FOOD.
JP2011046708A5 (en)
WO2008039406A3 (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11703726

Country of ref document: EP

Kind code of ref document: A2